MARKET

CDXS

CDXS

Codexis Inc
NASDAQ
6.50
+0.43
+7.08%
Closed 17:45 10/04 EDT
OPEN
6.26
PREV CLOSE
6.07
HIGH
6.68
LOW
6.26
VOLUME
727.36K
TURNOVER
--
52 WEEK HIGH
42.01
52 WEEK LOW
5.73
MARKET CAP
425.71M
P/E (TTM)
-22.2146
1D
5D
1M
3M
1Y
5Y
Codexis appoints Kevin Norrett as chief operating officer
Codexis (NASDAQ:CDXS) <a href="https://seekingalpha.com/pr/18960726...
Seekingalpha · 2d ago
Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field
REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent hosting of its in-person Protein Engineering Forum from Septem...
GlobeNewswire · 09/14 20:05
SPLK, WIX and HBAN are among after hour movers
Gainers: Quhuo  (QH) +38%. Splunk (<a href="https://seekingalpha...
Seekingalpha · 09/09 21:14
Analyst Ratings for Codexis
  Codexis (NASDAQ:CDXS) has observed the following analyst ratings within the last quarter:
Benzinga · 08/08 13:19
--HC Wainwright Adjusts Codexis' Price Target to $25 From $27, Reiterates Buy Rating
--HC Wainwright Adjusts Codexis' Price Target to $25 From $27, Reiterates Buy Rating
MT Newswires · 08/08 06:52
Codexis Q2 EPS $(0.04) Beats $(0.13) Estimate, Sales $38.41M Miss $38.55M Estimate
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 42.86 percent increase over losses of $(0.07) per share from the same
Benzinga · 08/04 22:28
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 71.43% and 1.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/04 22:05
Codexis: Q2 Earnings Insights
Codexis (NASDAQ:CDXS) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Codexis beat estimated earnings by 69.23%, reporting an EPS of $-0.04 versus an estimate of ...
Benzinga · 08/04 21:34
More
About CDXS
Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and sells enzymes and other proteins. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The Company has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. It also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The Company is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

Webull offers kinds of Codexis, Inc. stock information, including NASDAQ:CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.